Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Univax Biologics Inc.
Charles Noland of Dakin Securities reiterated a "buy" under $10 and a "strong buy" under
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury